Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) |
Z-CTLs |
Phase 1 Clinical |
Hunan Zhaotai Yongren Biotech |
Carcinoma, Non-Small-Cell Lung |
Details
|
FH-2001 |
FH-2001 |
Phase 1 Clinical |
Shanghai Fosun Pharmaceutical Development Ltd |
Solid tumours |
Details
|
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) |
|
Phase 1 Clinical |
The Second Hospital Of Nanjing Medical University |
Carcinoma, Hepatocellular |
Details
|
TT-00420/Atezolizumab |
|
Phase 1 Clinical |
Yaojie Ankang (Nanjing) Technology Co Ltd |
Gastrointestinal Neoplasms |
Details
|
FS 118 |
FS-118 |
Phase 2 Clinical |
Merck Serono, F-Star |
Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis |
Details
|
GT-90008 |
GS-19-PLB-1C; GT-90008; GS-19 |
Phase 1 Clinical |
Suzhou Kintor Pharmaceuticals Inc |
Solid tumours |
Details
|
BMS-936559 |
MDX-1105; BMS-936559 |
Phase 3 Clinical |
Bristol-Myers Squibb Company |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
CK-301 |
CK-301 |
Phase 1 Clinical |
Dana-Farber Cancer Institute |
Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
IMM-2510 |
IMM-2510 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours |
Details
|
Durvalumab/Gefitinib |
|
Phase 2 Clinical |
Medimmune |
Carcinoma, Non-Small-Cell Lung |
Details
|
Q-1802 |
Q-1802 |
Phase 1 Clinical |
Qiyu Biotechnology (Shanghai) Co Ltd |
Solid tumours |
Details
|
SG12473 |
SG12473; SG-12473 |
Phase 1 Clinical |
Hangzhou Sumgen Biotechnology Co Ltd |
Hematologic Neoplasms; Solid tumours |
Details
|
ACT-001 |
ACT-001 |
Phase 2 Clinical |
Accendatech |
Glioblastoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
ND-021 |
ND-021; NM21-1480; CS-2006; CS2006 |
Phase 2 Clinical |
Numab Therapeutics Ag, Cstone Pharmaceuticals |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Emdifen |
|
Phase 1 Clinical |
Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences |
Solid tumours |
Details
|
ABL-501 |
ABL-501 |
Phase 1 Clinical |
Abl Bio |
Solid tumours |
Details
|
Garivulimab |
BGB-A333 |
Phase 1 Clinical |
Beigene Ltd |
Solid tumours; Neoplasms |
Details
|
TQB-2450 |
APL-502; CBT-502; TQ-B2450 |
Phase 3 Clinical |
Cbt |
Stroke; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Liver Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Genital Diseases, Female; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Lymphoma, B-Cell; Solid tumours |
Details
|
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) |
LP-002 |
Phase 2 Clinical |
Taizhou Houde Aoke Technology Co Ltd |
Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma |
Details
|
SKB-337 |
SKB337; A-337; SKB-337 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
LY-3415244 |
LY-3415244 |
Phase 1 Clinical |
Eli Lilly And Company |
Solid tumours; Neoplasms |
Details
|
ABSK-043 |
ABSK043 |
Phase 1 Clinical |
Abbisko Therapeutics |
Solid tumours; Neoplasms |
Details
|
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) |
|
Phase 1 Clinical |
Jiangsu Huaiyu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
HB-0025 |
HB0025 |
Phase 1 Clinical |
Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
FAZ-053 |
FAZ-053; LAE-005; LAE005 |
Phase 2 Clinical |
Novartis Pharma Ag |
Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part |
Details
|
GR-1405 |
GR-1405 |
Phase 3 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd |
Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Lymphoma |
Details
|
GS-4224 |
GS-4224 |
Phase 1 Clinical |
Gilead Sciences Inc |
Solid tumours; Hepatitis B |
Details
|
Durvalumab/Selumetinib sulfate |
|
Phase 1 Clinical |
Astrazeneca Plc |
Neoplasms |
Details
|
Pd-1-pik |
Pd-1-pik |
Phase 1 Clinical |
Huashan Hospital Affiliated To Fudan University |
Glioblastoma |
Details
|
PRS-344 |
PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 |
Phase 2 Clinical |
Pieris Pharmaceuticals Inc, Laboratoires Servier |
Solid tumours |
Details
|
GNC-039 |
GNC-039 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis |
Details
|
BJ-005 |
BJ-005 |
Phase 1 Clinical |
Boji Biomedical Technology (Hangzhou) Co Ltd |
Solid tumours |
Details
|
Erfonrilimab |
KN-046; KN046 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd, Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms |
Details
|
PF-07257876 |
|
Phase 1 Clinical |
|
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics |
Solid tumours |
Details
|
Sudubrilimab |
HS-636 |
Phase 2 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Triple Negative Breast Neoplasms; Primary mediastinal B cell lymphoma |
Details
|
Human source and Fc engineered monoclonal antibody (MabSpace) |
MSB-2311 |
Phase 1 Clinical |
Mabspace Biosciences Co Ltd |
Solid tumours |
Details
|
BMS-986189 |
BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Sepsis |
Details
|
ALPN-202 |
ALPN-202 |
Phase 1 Clinical |
Alpine Immune Sciences |
Solid tumours; Lymphoma |
Details
|
IMM2505 |
IMM2505 |
Phase 1 Clinical |
Shenghe (China) Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
Opucolimab |
HLX-20 |
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Solid tumours; Neoplasms |
Details
|
BR-102 |
BR102 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
89Zr-KN035(Wuxi No. 4 People's Hospital) |
|
Clinical |
Wuxi No. 4 People |
Solid tumours |
Details
|
QLF31907 |
QLF31907; QLF-31907 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
Carrizumab |
|
Phase 2 Clinical |
|
Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma |
Details
|
IMC-001 |
IMC-001; STI-3031; STI-A1015 |
Phase 2 Clinical |
Sorrento Therapeutics |
Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|
LOR-S03 |
CDX-527 |
Phase 1 Clinical |
Celldex Therapeutics |
Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
TJ-L14B |
ABL-503; TJ-L14B/ABL503; ABL503 |
Phase 1 Clinical |
I-Mab Biopharma Co Ltd |
Solid tumours |
Details
|
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Peritoneal Neoplasms |
Details
|
PM-8001 |
6MW3111; PM-8001 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours; Lung Neoplasms |
Details
|
MT-6402 |
|
Phase 1 Clinical |
Molecular Templates |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung |
Details
|
MVR-C5252 |
C-5252; MVR-C5252 |
Phase 1 Clinical |
Immvira Co Ltd |
Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms |
Details
|
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) |
|
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd |
Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms |
Details
|
PM-1003 |
PM1003 |
Phase 2 Clinical |
Biotheus Inc |
Solid tumours |
Details
|
MCLA-145 |
MCLA-145 |
Phase 1 Clinical |
Incyte Corp, Merus |
Solid tumours |
Details
|
IGV-001 |
IGV-001 |
Phase 2 Clinical |
Thomas Jefferson University |
Glioblastoma |
Details
|
FS-222 |
FS-222 |
Phase 1 Clinical |
F-star Beta Ltd |
Neoplasm Metastasis |
Details
|
18F-BMS-986192 |
BMS-986192-[18F] |
Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
89Zr-durvalumab |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Head and Neck Neoplasms |
Details
|
Recombinant anti-PD-L1/TGF-β bispecific antibody |
Y101D; Y-101D |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd |
Solid tumours |
Details
|
IBI-318(Innovent Biologics/Eli Lilly And Company) |
LY-3434172; LY3434172; IBI-318 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company |
Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
IBI-323(Innovent Biologics) |
IBI-323 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
QLS31901 |
QLS-31901; QLS31901 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
CHECKvacc |
CF33-hNIS-antiPDL1 |
Phase 1 Clinical |
Imugene Ltd, City Of Hope National Medical Center |
Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
GNC-035 quadr-specific antibody(baili) |
GNC-035 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
HLX-301 |
HLX-301 |
Phase 2 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
Manelimab |
BCD-135 |
Phase 1 Clinical |
Biocad |
Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Pacmilimab |
CX-072 |
Phase 2 Clinical |
Cytomx Therapeutics |
Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma |
Details
|
Lodapolimab |
LY-3300054 |
Phase 1 Clinical |
Eli Lilly And Company |
Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
ATG-101 |
ATG-101 |
Phase 1 Clinical |
Antengene Corporation Co Ltd |
Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin |
Details
|
AN-4005 |
AN-4005 |
Phase 1 Clinical |
Hangzhou Adlai Nortye Biomedical Technology Co Ltd |
Solid tumours; Neoplasms; Lymphoma |
Details
|
TST-005 |
TST-005; TST005 |
Phase 1 Clinical |
Mabspace Biosciences Co Ltd |
Neoplasms |
Details
|
ADG-104 |
ADG-104; ADG104 |
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc |
Neoplasms |
Details
|
SHS-009 |
SHS-009; SH009; SH-009 |
Phase 1 Clinical |
Nanjing Sanhome Pharmaceutical Co Ltd |
Neoplasms |
Details
|
BPI-371153 |
BPI-371153 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Lymphoma |
Details
|
TS-1905 |
TS-1905; LY-01019; BA-1201 |
Phase 1 Clinical |
Shandong Boan Biotechnology Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung |
Details
|
INBRX-105 |
ES101; INBRX-105 |
Phase 2 Clinical |
Inhibrx |
Solid tumours; Thoracic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Esophageal adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
JS-003 |
JS-003 |
Phase 1 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Solid tumours |
Details
|
RC-98 |
RC-98; RC98 |
Phase 2 Clinical |
RemeGen Co Ltd |
Solid tumours |
Details
|
99mTc-NM-01 |
99mTc-NM-01 |
Phase 2 Clinical |
Nanomab Technology Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
GNC-038 |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Simridarlimab |
IBI-322 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Hematologic Neoplasms; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute |
Details
|
MAX-10181 |
MAX-10181; MAX-1 |
Phase 1 Clinical |
Guangzhou Maxinovel Pharmaceiticals Co Ltd |
Solid tumours |
Details
|
6MW-3211 |
6MW3211; 6MW-3211 |
Phase 2 Clinical |
Mabwell (Shanghai) Bioscience Co Ltd |
Neoplasms |
Details
|
INCB-086550 |
INCB-086550; INCB-86550 |
Phase 2 Clinical |
Incyte Corp |
Solid tumours; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular |
Details
|
RG-6084 |
RG-6084; RO-7191863 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Hepatitis B |
Details
|
TQB-2858 |
TQB-2858 |
Phase 2 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Pancreatic Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms |
Details
|
Cosibelimab |
TG-1501; CK-301 |
Phase 3 Clinical |
Tg Therapeutics |
Lymphoma; Carcinoma, Non-Small-Cell Lung |
Details
|
CA-170 |
AUPM-170; CA-170 |
Phase 1 Clinical |
Aurigene |
Solid tumours |
Details
|
Acasunlimab |
GEN1046; BNT-311; DuoBody-PD-L1x4-1BB; PD-L1x4-1BB |
Phase 2 Clinical |
Biontech Se, Genmab |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
SGN-PDL1V |
SGN-PDL1V |
Phase 1 Clinical |
Seagen Inc |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
BAT-7104 |
BAT-7104 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Neoplasms |
Details
|
Retlirafusp alfa |
SHR-1701 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
LBL-024 |
LBL024; LBL-024 |
Phase 2 Clinical |
Nanjing Leads Biolabs Co Ltd |
Solid tumours |
Details
|
ASC-61 |
ASC-61 |
Phase 1 Clinical |
Ascletis Pharma Inc |
Solid tumours; Neoplasms |
Details
|
KD-033 |
KD-033 |
Phase 1 Clinical |
Takeda Pharma |
Solid tumours |
Details
|
Bintrafusp alfa |
M-7824; GSK-4045154; MSB-0011359C |
Phase 3 Clinical |
Merck Serono |
Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
QL-415 |
QL-415 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
QL-301 |
QL-301 |
Phase 1 Clinical |
|
Neoplasms |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|